Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
Related Questions
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
When do you switch to a different DMT in multiple sclerosis patients planning for pregnancy?
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
